Axtria Targets AI Adoption Gap in Pharma Forecasting With Industry-Focused Webinar

A LinkedIn post from Axtria highlights what it describes as a gap between pharma companies’ prioritization of artificial intelligence in forecasting and its limited practical application. The post cites a figure that 82% of pharma organizations reportedly have not applied AI to a single core forecasting assumption, despite AI being characterized as a top priority for forecasting teams.

According to the post, Axtria plans to address this issue in an upcoming Ignite webinar that combines findings from its 2026 Life Sciences Forecasting Benchmarking Report with practitioner perspectives. The event is positioned as examining where AI can add value without overhauling workflows, suggesting a focus on incremental, operationally feasible adoption.

The LinkedIn content also references “practical GenAI entry points” for current forecasting practices and what is described as being needed to move forward with organizational confidence. A featured speaker from AstraZeneca, alongside Axtria’s own forecasting leadership, indicates cross-company engagement that may enhance the perceived relevance of the discussion for large biopharma stakeholders.

For investors, the post suggests Axtria is actively positioning itself as an advisor and solutions provider around AI-enabled forecasting in life sciences. If this thought-leadership activity translates into increased demand for Axtria’s analytics and planning offerings, it could support revenue growth and deepen its role in strategic decision support across pharma clients.

More broadly, the emphasis on AI-driven forecasting underscores an industry trend toward data-intensive, technology-enabled commercial planning. Companies that can operationalize AI in forecasting may improve resource allocation, launch planning, and revenue predictability, which could, over time, influence competitive positioning and valuation dynamics in the life sciences sector.